Venture Advisory Board

OTT has created a Venture Advisory Board to better accommodate the constant growth and challenges facing its start-up opportunities. The valley of death funding gap has expanded tremendously in recent years as funding for new and established companies has become increasingly challenging. In addition, regulatory and reimbursement concerns continue to discourage new opportunities. New companies contribute significantly to job growth and they have been vital to Emory's ability to bring new discoveries to market. This Board consists of successful, experienced entrepreneurs, venture capitalists, industry experts, and legal experts.

 
Gutch

Michael Gutch, PhD
Managing Director, MedImmune Ventures

Professional Experience
Mike had experience as both a corporate and private venture capital investor prior to joining MedImmune Ventures in September 2011. Before MV, Mike was a Director with H.I.G. BioVentures, a life-science focused investment fund and prior to that was a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Eli Lilly, Mike was also in the Corporate Financing and Investment Banking group, where he focused on mergers and acquisitions and licensing transactions.

Boards & Counsels
Mike currently serves as a member of the Board of Directors for Southeast BIO, a member of the Johns Hopkins Alliance for Science & Technology Development, and a member of the Business Advisory Boards for the Alzheimer’s Drug Discovery Foundation and National Brain Tumor Society.

Education
Mike earned his PhD in cellular and molecular pathology from the State University of New York at Stony Brook and was a post-doctoral research fellow at both UCSF and the Cold Spring Harbor Laboratories. He earned his MBA in finance from Indiana University.

Honors

 
Hillstead

Richard A. Hillstead, PhD, FAHA
Partner, Georgia Venture Partners

Experience
Rick Hillstead has been actively involved in the design and development of medical devices since 1983. He held several progressive, Product Research and Development positions with Cordis Corporation (Johnson & Johnson) from 1987 to 1993 where he pioneered device development in the Cordis Coronary Stent program as a Senior Corporate Research Engineer. He then directed new technology development for Novoste Corporation from 1993 until 1999. Novoste’s primary focus was a technology jointly developed with Emory University in the field of intravascular brachytherapy catheters and systems for the treatment of coronary restenosis following angioplasty and stenting. In 1999 he became a founding member and Chief Science Officer (CSO) of The Innovation Factory (TIF), a private medical device incubator in Duluth, GA. As CSO at TIF, he was primarily responsible for R&D in a wide variety of Life Science ventures. His focus at TIF was to evaluate life science technologies based on technical merit, intellectual property strength, regulatory and clinical research path, market potential, as well as critical assessment regarding a given ventures likelihood to secure funding and the probability of a meaningful exit. His areas of expertise include interventional cardiology, minimally invasive surgery, orthopedics, aesthetics, and ophthalmic devices. Companies he co-founded while at TIF include Neuronetics, Liposonix, Acufocus, NeoVista, Halscion, AqueSys, Cerebral Vascular Applications, Cellutions, and Novalign. He is also a principal partner (non-active) and founding member in Accuitive Medical Ventures (AMV) I and II. AMV is a venture capital fund with a strategic focus on medical devices. He has negotiated life science development agreements with academic institutions and individuals in the UK, Australia, and throughout the US. He has managed numerous, diverse, multi-disciplinary development teams from product concept through sales release. He often speaks on the importance of Innovation and Intellectual Property to the entrepreneurial process in the medical device industry at conferences and scientific sessions. In 2008 he joined Georgia Venture Partners (GVP), Atlanta GA where he is presently a partner (http://www.georgiavc.com/ourteam.shtml). He is an accomplished inventor named on approximately seventy five issued U.S. patents and pending applications and dozens of international patents. His intellectual property has been referenced in well over three thousand issued U.S. patents and pending patent applications. He has given testimony in the field of interventional cardiology devices in U.S. courts and arbitrations and served as an expert witness to the High Court of Justice in the UK as well as multiple cases in Germany and The Netherlands. He has played a pivotal role in the development of numerous, commercially successful medical devices, often from invention to commercialization.

Boards & Counsels
Dr. Hillstead is most recently serving as an advisor to the US Food and Drug Administration (FDA), in the capacity of Entrepreneur in Residence (EIR) with the Center for Devices and Radiologic Health (CDRH). This program is supported by The White House Office of Science and Technology Policy as a component of the administration's Strategy for American Innovation. His current project at the FDA is focused on helping to streamline FDA approval to reimbursement as a Strategic Team member. He is also the former Chairman and CEO of Biofisica Inc. He is a past Chairman and co-founder of Cerebral Vascular Applications, Inc. (CVA), a company dedicated to reducing the incidence of stroke through closure of the atrial appendage of the heart via minimally invasive techniques.

He is a Fellow in the American Heart Association on the Council of Clinical Cardiology; Fellow on the Council on Nutrition, Physical Activity, and Metabolism; and a current member of the Stroke Council and the Council on Cardiopulmonary Resuscitation.

Education
Dr. Hillstead holds a BS in engineering management and an MBA from Nova Southeastern University, and a PhD in Business Administration from Southwest University.

Honors

 
Knowles

Sherry M. Knowles, Esq.
Principal, Knowles Intellectual Property Strategies, LLC

Experience
Sherry M. Knowles is an intellectual property attorney with over 25 years of experience in global corporate and private practice. From 2006-2010, Ms. Knowles was the Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, where she served as the worldwide head of patents for both litigation and transactional matters, and managed a global department of over 200 people in 12 offices. At GSK, Ms. Knowles was a member of the Scientific Advisory Board, the Technology Investment Board, the Product Management Board, the Legal Management Team and she led the Global Patents Executive Team. In 2010, Ms. Knowles left GSK to start Knowles Intellectual Property Strategies (www.kipsllc.com), which provides strategic legal and business advice to companies developing, commercializing, litigating and monetizing assets, with a focus on pharmaceutical, biotech, medical device and chemical inventions.

Boards & Counsels

Education

Honors
In 2008, Managing IP Magazine named Ms. Knowles one of the top 10 most influential people in Intellectual Property, referring to her as a “Patent Owner’s Advocate.” In 2010, the New Jersey Intellectual Property Lawyers Association awarded GSK, with Ms. Knowles as the representative, the Jefferson Medal for exceptional contribution to Intellectual Property. In 2010, Managing IP Magazine named the GSK Global Patent Team the “In-House IP Team of the Year” for 2009 for the constructive approach to IP in the developing world, the engagement with public policy in Europe and the successful resolution of litigation in the US which prevented the US Patent Office from issuing regulations that would have harmed innovation across all industries. In 2011, Intellectual Asset Management Magazine listed Ms. Knowles among the top 50 individuals, companies and institutions that have shaped the IP marketplace over the last eight years. Ms. Knowles is also listed in the 2011 IAM 250 “World’s Leading IP Strategists,” published by IAM Magazine and the 2012 and 2013 IAM 300 “World’s Leading IP Strategists.

 
Patrick

Timothy Patrick
President and CEO, Carticept Medical, Inc. and Cartiva, Inc.

Experience
Tim Patrick has over 30 years of experience in the medical device industry and is President and CEO of Carticept Medical, Inc., and Cartiva, Inc., both located in Alpharetta, GA. Carticept Medical has developed a platform technology, the Navigator® Delivery System, to improve the safety, efficiency and accuracy of many common injection procedures. The Navigator Delivery System is the first and only FDA-cleared computer controlled medication delivery system for intra-articular injections. Cartiva, Inc. was spun out from Carticept Medical in December 2011; its first commercial product is Cartiva Synthetic Cartilage Implant (Cartiva SCI), a proprietary PVA cryogel device designed to replace or repair worn or damaged cartilage. Prior to founding Carticept Medical in 2005, Tim was President, CEO and co-founder of Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005 for approximately $187 million. Prior to co-founding Proxima Therapeutics in 1996, Mr. Patrick was President of Gesco International, the leading manufacturer of peripherally inserted central venous catheters. Before serving as President of Gesco International, he ran two high growth divisions for McGaw Inc., an oncology drug provider. He also held a number of sales and sales management positions at American Hospital Supply Corporation. Tim is an inventor on several patents related to Carticept’s automated injection system and others related to localized radiation delivery systems.

Boards & Counsels
Tim has served on the Board of Directors of the Advanced Medical Technology Association (AdvaMed). He is currently on the Board of the Georgia Tech Coulter Grant Committee; serves on the Board of Georgia Bio and chairs its Medical Device Committee; and is a member of the Directors Circle at Yerkes National Primate Research Center.

Education
He earned his BA in Zoology from Miami University in Ohio.

Honors

 
Richard

John P. Richard, MBA

Interim CEO, QUE Oncology

Experience
Mr. Richardcurrently serves as a Partner with Georgia Venture Partners, Senior Venture Partner with Phase4 Ventures, Interim CEO of QUE Oncology, and Senior Business Advisor to Albireo AB and Nabriva AG. Previously, he was Executive Vice President, Business Development, at SEQUUS Pharmaceuticals, a biotechnology company that successfully developed and launched two new pharmaceuticals. Mr. Richard was responsible for negotiating the acquisition of SEQUUS by ALZA Corporation. Prior to SEQUUS, Mr. Richard headed business development for VIVUS and Genome Therapeutics Corporation. Earlier he co-founded and served as original CEO of IMPATH Inc., a leading cancer diagnostics business acquired by Genzyme.

Boards & Counsels
He serves on the boards of several biotechnology companies including Targacept, Inc.

Education
Mr. Richard received his MBA from Harvard Business School and his BS from Stanford University.

Honors

 
Schutter

Ed Schutter, MBA
President and CEO, Arbor Pharmaceuticals

Experience
Ed Schutter is a thirty year veteran of pharmaceutical industry currently serving as President and CEO of Arbor Pharmaceuticals. Arbor generates over $200 million in annual sales and has seven branded and over twenty-five generic products in development. Prior to Arbor, Ed served as President of Sciele Pharmaceuticals which sold to Shionogi & Co. Ltd. for $1.4 billion in 2008. Prior to his Sciele experience, Ed served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles in sales, marketing and business development at the U.S. subsidiary of Solvay during his twenty years with the organization. Ed began his pharmaceutical career with Reid-Provident Laboratories, a small entrepreneurial pharmaceutical company based in Atlanta, GA. Ed was also a co-founder of North Hampton Pharmaceuticals which later changed its name to Ventrus Biosciences, a Nasdaq listed company. In addition to his investment in Arbor, Ed is currently an angel investor in several biotech, branded and generic pharmaceutical companies in the U.S. and Canada.

Boards & Counsels
Ed currently serves on the board of Georgia Bio, the American Diabetes Association and the board of visitors for Mercer University College of Pharmacy and Health Sciences.

Education
Ed has a BSPS from Mercer University and a MBA from Kennesaw State University.

Honors

 
Snowdy

Stephen Snowdy, PhD

Owner, Ansley Venture Consulting

Experience
Dr. Snowdy is a scientist, serial entrepreneur, and an early-stage medical venture capitalist. He is Interim CEO of the contact lens company Visioneering Technologies (Atlanta), Chairman and CEO of a Phase 2 osteoarthritis company, Calosyn Pharma (Atlanta and Louisiana), and is managing a new cancer drug startup out of Emory University and Georgia Tech. Dr. Snowdy is also a grants manager for the Wallace H. Coulter Foundation, where he reviews translational grants for several universities, and is a faculty member of the Coulter College, a translational research educational program administered by the Biomedical Engineering Society.

Boards & Counsels
Dr. Snowdy serves on the Biomedical Engineering Advisory Board at Georgia Tech and Emory.

Education
Dr. Snowdy simultaneously earned a PhD in Neurobiology and an MBA at the University of North Carolina, Chapel Hill. He obtained a BS degree in chemistry from the University of Florida, where he also completed two years of post-baccalaureate study in cardiopharmacology. Dr. Snowdy's academic training followed service in the United States Navy Special Forces.

Honors

 
Yates

John Yates, JD
Partner, Morris, Manning & Martin, LLP

Experience
John C. Yates is the partner-in-charge of the Technology Practice. Mr. Yates is one of the pioneers of the technology law field and has been practicing exclusively in this area for over 30 years. The firm’s technology practice has represented hundreds of technology companies and provides legal services in such areas as IPOs, mergers and acquisitions, patent prosecution, Internet law, biotech and medical devices, ecommerce/distribution, corporate finance and venture capital, international law and dispute resolution. Mr. Yates is also a member of the firm’s IndUS Group, Data Center Law Group and Mobile Law & Compliance Group.

Mr. Yates’is articles have been cited in the computer law area, including citation by the U.S. Supreme Court in Kodak vs. Image Technical Services. He is a co-author of articles published in The Law and Business of Computer Software and The Handbook of Business Management. Mr. Yates is frequently quoted in business publications, including The Wall Street Journal, The Economist, and the Atlanta Business Chronicle. Mr. Yates has also been recognized in a Harvard Business School case study (“Ockham Technologies: Living on the Razor’s Edge”) as a leading lawyer representing fast growth companies. Mr. Yates is a frequent speaker at national and international business and technology law organizations. He has delivered more than 250 speeches during his career. He has also spoken at annual computer law seminars sponsored by the Georgia Bar Association, North Carolina Bar Foundation, Minnesota Computer Law Institute and American Bar Association’s Section of Science and Technology. Mr. Yates is currently co-authoring a book, entitled “The Art of Business Friendship,” and is a columnist for various online computer and legal publications.

Boards & Counsels
Mr. Yates co-founded the Southeastern Software Association (SSA), Southeastern Medical Device Association (SEMDA) and Technology Association of Georgia (TAG). He has founded and been a member of the Board of Directors of leading technology organizations for over two decades. He serves on the editorial board of leading technology publications. In 2003, Mr. Yates was Chairman of the Georgia Technology Celebration, the largest gathering of technology executives in Georgia’s history.

Education

Honors
In 2001, the Technology Association of Georgia honored Mr. Yates by making him the first recipient of the “Leader of Influence Award” for his outstanding service to the region’s technology community. He has also been selected by eCompanies as one of the “Technology Leaders in Atlanta” and by the Atlanta Business Chronicle as one of the “Most Influential Leaders in Atlanta.” In 2002, the United Way of Metropolitan Atlanta created the John Yates Award for Community Leadership honoring his work on behalf of the community as co-chair of the United Way’s Atlanta Technology Initiative for 2001-02. The award is presented to the United Way campaign member who surpasses expectations and inspires others to use their unique gifts in ways that impact the community. He also received the 2003 Community Builder Award from the Technology Association of Georgia for his service on behalf of the technology community in the state. He was selected as a “Georgia Super Lawyer” in the fields of Business/Corporate (Technology) in 2004 - 2012 and is among the top five percent of the state’s attorneys to be so honored.